Plain-English translation of NCT06472908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether colchicine, a medication that reduces inflammation, can help prevent serious heart complications after you receive a stent to open a blocked heart artery. About 8,862 people will receive either a higher dose of the medication, a lower dose, or a placebo (a pill with no active ingredient) to see which approach works best. This study will track participants for up to 2 years to see if the medication reduces the risk of future heart problems.
After a stent is placed in the heart, inflammation can sometimes trigger additional problems. Researchers want to know whether this medication, which fights inflammation, can safely reduce these risks and improve long-term outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will take one pill by mouth every day for up to 2 years — either the higher-dose medication, lower-dose medication, or placebo (you won't know which). You'll visit the clinic at months 1, 6, 12, 18, and 24, with phone check-ins in between. The research team will also contact you every 3 months to ask about any side effects or health changes. Throughout the study, you'll continue receiving all your regular heart medications and care.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China